ClinicalTrials.gg
CompletedNCT01094249Updated Apr 8, 2014

A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder

A Phase 1 interventional study of divalproex sodium ER/paliperidone ER in Schizophrenia, Bipolar Disorder and Psychotic Disorders, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-04-08.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing Valproic Acid in Schizophrenia — none open to participants now, none under way, none of them phase 3. Valproic Acid · Schizophrenia.

Enrollment
10th of 10
9 · median 85
Started
2009
with 1 other
Phase 1
2 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
2 of 10
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Among the 10 studies testing Valproic Acid in Schizophrenia, this one is the 10th largest by enrollment, is one of 2 that started in 2009, is one of 2 in phase 1, and was the 6th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 10 studies testing Valproic Acid in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

Where they have run

About Valproic Acid

Valproic Acid: first FDA approval 1978 (DEPAKENE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing Valproic Acid in Schizophrenia as a file.
02

Study summary

The purpose of this study is to evaluate the potential effect of multiple oral doses of an extended release formulation of paliperidone on the pharmacokinetics (blood levels) of valproic acid (VPA) in patients with schizophrenia, bipolar I disorder, or schizoaffective disorder.

Read the detailed description

This is an open-label (patient will know the identity of the study drug they are taking) study in patients diagnosed with either schizophrenia, bipolar I disorder, or schizoaffective disorder who currently receive treatment with valproic acid, sodium valproate, or divalproex sodium. The primary purpose of the study is to determine the effect, if any, that multiple doses of paliperidone extended release (ER) tablets has on the pharmacokinetics (ie, blood levels) of valproic acid administered in the study as divalproex sodium extended release (ER). Divalproex sodium consists of a compound of sodium valproate and valproic acid in a 1:1 molar relationship in an enteric coated form. Approximately 16 patients will take part in the study. The study will last approximately 41 days and participation in this study will require a minimum of 5 overnight stays up to a maximum of 13 overnight stays during study drug treatment. The study will consist of a screening period that will occur up to 21 days before study treatment, a 13-day treatment period, and a posttreatment period that will include a follow-up visit 1 week after end-of-treatment procedures are performed. The purpose of the screening visit is to see patients meet all of the requirements to participate in the study. At the screening visit, after patients read and provide written informed consent acknowledging their willingness to participate in the study, the following procedures will be performed: 1) information regarding medical, psychiatric, and surgical history and medications currently taken will be collected, 2) a physical examination will be performed, 3) vital signs (blood pressure) and an electrocardiogram (ECG, a painless test to measure the electrical activity of the heart) will be assessed, 4) a blood sample for routine laboratory tests as well as to test for hepatitis B, hepatitis C, and human immunodeficiency virus (HIV) (and to check for pregnancy in women of child-bearing potential) will be collected, 5) a urine sample will be collected for routine laboratory testing including testing for drugs of abuse, and 6) an alcohol breath test will be performed. Patients who meet entry criteria for the study will be asked to check-in at the study clinic the evening before the first administration of study drug and will stay overnight at the clinic for at least 5 days or through Day 13 (approximately 2 weeks). During overnight stays at the clinic, patients will be required to eat and drink only the meals and beverages provided at the clinic. Patients will take each study drug orally (by mouth) in the following order on the days specified: divalproex sodium ER once daily for 7 days (Day 1 through Day 7) followed by divalproex sodium ER once daily in combination with paliperidone ER once daily for 7 days (ie, Days 8 through Day 12). During the study, patients will have blood samples taken from a vein in their arm using a needle (or flexible tube) at specified times during the study to determine the concentration of drugs in their blood. On Day 13 (or at the time of early withdrawal from the study) after the last blood sample for drug levels has been collected, patients will undergo end-of-study procedures that will include a physical examination, measurement of vital signs, and an ECG. A blood and urine sample for routine laboratory testing will also be collected during the end-of-study procedures to check the patients general health (and to check for pregnancy in women of child-bearing potential). After all end-of-study procedures have been completed, patients will leave the study clinic and return in about 1 week for a posttreatment follow-up visit where their overall general condition and the occurrence of any adverse events will be assessed. The primary objective of this study is to assess the potential effect of multiple doses of paliperidone ER tablets on the steady state pharmacokinetics of VPA. Steady state is achieved when drug concentrations in the blood are stable (ie, when the rate of drug absorption equals the rate of drug elimination in the body). Patients will also be monitored for safety from the time that they sign the informed consent form through to the end of the study (ie, posttreatment follow up visit). Safety will include monitoring adverse events, changes in clinical laboratory test results, ECG parameters, vital signs measurements, physical examination findings, the severity of the patients general condition, and concomitant medications (medications other than study drugs taken by patients) throughout the study period. All patients will receive a single oral (by mouth) daily dose of divalproex sodium ER (dose depended on the patients prescreening therapeutic dose) on Days 1 through 7 and divalproex sodium ER once daily in combination with one 12mg tablet of paliperidone ER once daily on Days 8 through 12. All study drugs are to be swallowed whole with water.

03

Conditions studied

  • Schizophrenia
  • Bipolar Disorder
  • Psychotic Disorders

Keywords

  • Paliperidone ER
  • INVEGA
  • Divalproex sodium
  • Depakote ER
  • Valproic acid
  • Pharmacokinetics
  • R076477BIM1004
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of schizophrenia or schizoaffective disorder according to the , Fourth Edition (DSM-IV)
  • Is clinically stable with no psychiatric hospitalization or change in existing mood stabilizers, antipsychotic, or anti-manic drugs for 1 month before screening
  • Taking valproate (valproic acid, sodium valproate, or divalproex sodium) for a minimum of 4 weeks before screening with a stable therapeutic dose for a minimum of 2 weeks and have confirmed therapeutic blood concentrations at screening
  • If a woman, be , surgically sterile, abstinent, or, if sexually active, be practicing an effective method of before entry and throughout the study
  • If a man, agrees to use an adequate contraception method as deemed appropriate by the Investigator and to not donate sperm using the study and for 3 months after receiving the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Meet criteria for rapid cycling if primary diagnosis is bipolar I disorder
  • DSM-IV diagnosis of alcohol or substance abuse with the exception of nicotine or caffeine dependence, within 12 months before screening
  • Current suicidal ideation or violent tendencies at the time of screening
  • History of neuroleptic malignant syndrome, any (with exception of basal cell carcinoma) within the past 5 years, any severe pre-existing gastrointestinal narrowing, or any history (or presence) of any cardiovascular, respiratory, neurologic, renal, hepatic, gastrointestinal, endocrine, hematologic, or immunologic disease
  • moderate or severe tardive dyskinesia at the time of screening
  • known allergy or intolerance of study drugs (ie, paliperidone, the parent compound risperidone, valproic acid, sodium valproate, or divalproex sodium) or any of the of the formulations (eg, lactose)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    001

    divalproex sodium ER/paliperidone ER Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12

    Drug: divalproex sodium ER/paliperidone ER

Interventions

  • Drugdivalproex sodium ER/paliperidone ER

    Drug pages: Valproic Acid · Paliperidone

    Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12

06

What researchers measure

Primary outcomes

  1. To assess the potential effect of multiple doses of paliperidone ER tablets on the steady state pharmacokinetics of VPA.

    Time frame: Blood samples collected at specified times on Days 4 through 13.

Secondary outcomes

  1. To evaluate safety and tolerability of paliperidone ER coadministered with divalproex sodium ER

    Time frame: From time of screening (Day -21 up to Day -2) through the posttreatment follow-up visit 1 week after the end-of-study visit (Day 13 or time of early withdrawal from study)

07

Study locations

3 sites
  • Kissimmee, Florida, United States
  • Austin, Texas, United States
  • Portsmount, Virginia, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2010
First posted
Mar 26, 2010
Start
Feb 2009
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Last update
Apr 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01094249
Responsible party
Sponsor
First posted
Mar 26, 2010
Start date
Feb 2009
Primary completion
Apr 2009
Completion
Apr 2009
Last update
Apr 8, 2014

Study contacts

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valproic Acid · Paliperidone

Start the discussion